The commercial function isn't just marketing. Its critical purpose is to ensure the healthcare delivery system is equipped to receive a new therapy. A great product is merely "table stakes"; adoption hinges on overcoming systemic barriers between regulatory approval and actual patient access.

To ensure a successful drug launch, biotech companies must start their commercialization planning at least 18 months in advance. This lead time is essential for deeply understanding the patient journey, identifying treatment barriers, and aligning clinical trials with outcomes that truly matter to patients and payers.

Many firms view patient engagement as a compliance task that adds cost. However, data shows integrating patient experience into development from the start speeds up clinical trial recruitment and execution, reduces FDA amendments, and accelerates time-to-market, providing clear ROI.

While you cannot promote a MedTech product before regulatory approval, you can and should promote the problem it solves. This 'problem marketing' strategy rewires the audience's thinking, making them feel the pain of the status quo. By the time your product launches, the market is already primed to seek your solution.

The reality of hospital value analysis committees means product adoption takes years. Entrepreneurs must build this lengthy timeline into financial models and fundraising to ensure survival, rather than projecting rapid uptake.

Gaining FDA approval is not the finish line. Many innovative devices fail because they lack a clear reimbursement strategy. Founders must build the economic case for payers and providers in concert with their clinical and regulatory strategy from day one.

Early-stage MedTech companies often have a limited, narrow understanding of their market size and product-market fit. Their intense focus on product development and regulatory hurdles causes them to neglect crucial commercialization planning, creating a major strategy gap post-approval.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

Many MedTech companies mistakenly believe a clinically superior product will automatically win market share. This is false. Market adoption is not automatic; it must be designed as intentionally as the product itself to overcome the powerful inertia of the status quo and make the market mentally ready for change.